Key features and details
- Suitable for: Blocking
Product nameHuman LOXL1 peptide
See all LOXL1 proteins and peptides
Purity70 - 90% by HPLC.
Predicted molecular weight63 kDa
Our Abpromise guarantee covers the use of ab97928 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
- Lysyl oxidase like 1
RelevanceLOXL1 is a member of the lysyl oxidase gene family. The prototypic member of the family is essential to the biogenesis of connective tissue, encoding an extracellular copper-dependent amine oxidase that catalyses the first step in the formation of crosslinks in collagens and elastin. A highly conserved amino acid sequence at the C-terminus end appears to be sufficient for amine oxidase activity, suggesting that each family member may retain this function. The N-terminus is poorly conserved and may impart additional roles in developmental regulation, senescence, tumor suppression, cell growth control, and chemotaxis to each member of the family. LOXL1 is active on elastin and collagen substrates. Genetic variations in LOXL1 are associated with risk of developing exfoliation syndrome (XFS) [MIM:177650]; also called exfoliation glaucoma (XFG). Exfoliation syndrome (XFS) is characterized by accumulation of abnormal microfibrillar deposits that line the aqueous bathed surfaces of the anterior segment of the eye. The prevalence of XFS increases with age, and a number of studies have pointed to a geographical clustering of XFS, although this condition is found worldwide; reported prevalence rates average about 10 to 20% of the general population over age 60.
Cellular localizationSecreted, extracellular space.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab97928 has not yet been referenced specifically in any publications.